Non-obviousness and Screening

The paper offers a novel justification for the non-obviousness patentability requirement. An innovation involves two stages: research results in a technology blueprint, which development transforms into a profitable activity. An innovator, who is either efficient or inefficient, must rely on outside finance for the development. Only patented technologies are developed. Strengthening the non-obviousness requirement alleviates adverse selection by discouraging inefficient innovators from doing research, but creates inefficiencies by excluding marginal innovations. We show that it is socially optimal to raise the non-obviousness requirement so as to exclude bad innovators; we also provide several robustness checks and discuss the policy implications

Project risk evaluation by using a new fuzzy model based on Elena guideline

The complexity and dynamics of the executive projects have coped contractors with substantial hazards and losses. Project risk management is a critical tool for authority to improve its performance and secure the success of the organization. However, a number of standards and approaches have been developed to formulate the projects based on their risks. The Elena guideline is a systematic standard developed by Iran Project Management Association. This guideline provides the full cycle of the risk management process. Risk evaluation is the key part of the risk management process. On the other hand, different techniques have been developed to model a risk evaluation problem. Fuzzy inference system is one of the most popular techniques that is capable of handling all types of the uncertainty involved in projects. This paper proposes a three-stage approach based on the fuzzy inference system under the environment of the Elena guideline to cope with the risky projects. Finally, an illustrative example of the risk evaluation is presented to demonstrate the potential application of the proposed model. The results show that the proposed model evaluates the risky projects efficiently and effectively

The Female Reproductive Cycle of the Bedriaga Plate-Tailed Gecko, Teratoscincus bedriagai

The Bedriaga Plate-tailed Gecko, Teratoscincus bedriagai Nikolsky, 1900, is distributed in the northern and eastern desert basins of the Central Plateau of Iran, Sistan, and the desert regions of southern Afghanistan. Iranian specimens are believed to be rare in collections. In this study, the reproductive cycle of this species has been investigated through focusing on oogenesis from 5 April to 5 August, 2013. Generally, 15 adult females were collected by hand at midnight from southern parts of Damghan County, situated in Semnan Province of Iran. Ovaries were removed and processed for the purpose of histological and morphometric studies. The results revealed that oocyte growth starts in early April and terminates in late July. Moreover, mating commences in spring, especially at the beginning of May, with oviposition occurring from late May to late July. Approximately, 1 to 2 eggs are laid by females per clutch with the possibility of producing a secondary clutch later in the season. The maximum reproductive activity takes place in May and continues with a decreasing trend in June and more reduction in July and finally ends in August. No significant difference was observed between right and left side of reproductive system. Therefore, oogenesis occurs from April to July, while T. bedriagai follows an oogenic cycle typical for temperate species

A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer

Prostate cancer is malignant cancer leading to high mortality in the male population. The existence of suppressive cells referred to as tumor-associated macrophages (TAM) is a major obstacle in prostate cancer immunotherapy. TAMs contribute to the immunosuppressive microenvironment that promotes tumor growth and metastasis. In fact, they are main regulators of the complicated interactions between tumor and surrounding microenvironment. M2 macrophages, as a type of TAMs, are involved in the growth and progression of prostate cancer. Recently, they have gained remarkable importance as therapeutic candidates for solid tumors. In this review, we will discuss the roles of M2 macrophages and worth of their potential targeting in prostate cancer treatment. In the following, we will introduce important factors resulting in M2 macrophage promotion and also experimental therapeutic agents that may cause the inhibition of prostate cancer tumor growth. Copyright© Bentham Science Publishers; For any queries, please email at [email protected]